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ABSTRACT
The majority of HIV-Herpes nucleoside analogues share a common mode of action, which is 
conversion via three successive phosphorylations, to their bioactive 5’-triphosphate forms by cellular 
or viral induced kinases. The protide strategy aims to deliver the monophosphate form of the parent 
nucleoside, in order to by-pass the first phosphorylation step and thus, the need for kinase-mediated 
activation. Indeed, a number of protide analogues have retained full anti-viral activity in 
kinase-deficient cells, suggesting that the protides effectively deliver the 5’-monophosphate forms 
intracellularly. In this paper the phosphoramidate derivatives of the thymine nucleoside analogues, as 
well as the 3′-amino-AZT derivative were synthesized and assayed for their antiviral activities. These 
derivatives exhibited poor activities, when compared to the parent nucleoside, indicating a lack of 
successful nucleotide delivery. Nevertheless, the formation of by-products during the synthesis of 
phosphoramidates via the phosphorochloridate strategy was overcome by controlling the conditions 
of the reaction and especially by choosing a selective coupling reagent, such as tBuMgCl or N-methyl 
imidazole to avoid any N-1 or 3′-phosphorylation. It is also clear from the results that 
phosphoramidates were sensitive to harsh conditions and reagents such as hydrogenation. The 
addition of the phosphochloridate should always be left to the last stage.   
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ABSTRAK
Majoriti analog nukleosida HIV-Herpes berkongsi satu mekanisma umum, iaitu penukaran melalui tiga 
pemfosforilan berturut-turut, kepada bentuk bioaktif 5'-trifosfat oleh kinase selular atau virus yang 
teraruh. Strategi protid bertujuan untuk memperolehi bentuk nukleosida induk monofosfat, bertujuan 
untuk memintas langkah pemfosforilan yang pertama. Oleh itu pengaktifan kinase-perantara adalah 
diperlukan. Sejumlah analog protid telah menahan aktiviti antivirus penuh dalam sel-kurang kinase, 
mencadangkan protid telah dengan berkesan membebaskan bentuk-bentuk 5'-monofosfat secara 
intrasel. Dalam kertas ini, terbitan fosforamidat analog nukleosida timina, serta terbitan 3’-amino-AZT 
telah disintesis dan dicerakin untuk menghasilkan aktiviti-aktiviti antivirus. Bentuk terbitan ini 
menunjukkan aktiviti yang sedikit, bila dibandingkan dengan induk nukleosida, menandakan 
penghasilan nukleotida yang kurang berjaya. Bagaimanapun, pembentukan produk sampingan semasa 
sintesis fosforamidat melalui strategi fosforokloridat telah diatasi dengan mengawal keadaan tindak 
balas, terutamanya dengan memilih reagen pergandingan yang sesuai seperti tBuMgCl atau N-metil 
imidazola bagi mengelakkan sebarang pemfosforilan N-1 atau 3’. Adalah jelas daripada hasil keputusan 
ini bahawa fosforamidat adalah sensitif terhadap keadaan dan reagen tegar seperti penghidrogenan. 
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Penambahan fosfokloridat hanya boleh dibuat pada tahap terakhir.
Kata kunci: HIV, VZV, HCMV, HSV, CBV (karbovir), 882C (netivudin), AZT, TK (kinase tirosina)
_________________________________________________________________________
INTRODUCTION
The propynyl substituent of netivudine (882C) makes it a particularly good substrate for viral kinases, 
especially that encoded by VZV. 882C is indeed a highly selective agent for VZV as it is inactive against 
HSV-1 and HSV-2. This potent selectivity between the herpes viruses is due to 882C monophosphate 
being an excellent substrate for the second phosphorylation by the VZV encoded kinase enzyme 
acting as TK. Unfortunately, netivudine is a specific anti-VZV agent with little anti-HCMV activity 
(Rahim et al., 1992). This is due to the poor phosphorylation of 882C in HCMV infected cells. The first 
phosphorylation step is rate-limiting, and then successful intracellular phosphate delivery technology 
may confer anti-HCMV activity on this compound. A number of symmetric and asymmetric 
5’-phosphate esters of the potent anti-varicella-zoster virus (VZV) agent netuvidine were prepared as 
potential lipophilic, membrane soluble prodrugs of the bio-active phosphate forms. However, all of 
the phosphate esters including the 5'-[phenyl methoxyalaninyl] phosphate derivative were inactive 
against HCMV, HSV-2, VZV, HIV-1 (McGuigan et al., 1996; McGuigan et al., 1998). It was anticipated 
that reduction of the triple bond localised at C-5 of 882C (compound 1) to alkene or alkane could 
improve the activity of this 5-substituted uracil nucleoside. The reduction of the side chain may form 
a better substrate for the HIV reverse transcriptase. The corresponding phosphoramidate was also 
synthesized in the hope that the use of the masked phosphate ester may have the potential to generate 
a broader spectrum anti-viral agent. 
A second interesting nucleoside analogue; 3’-Azido-3’deoxythymidine (AZT), a significant 
clinically used agent for HIV (Yarchoan et al., 1986) is a potent inhibitor of the in vitro replication and 
cytopathic effect of HIV. This drug is a thymidine analogue in which the 3’-hydroxy (-OH) group is 
replaced by an azido (-N3) group. AZT is converted to a triphosphate form by cellular enzymes and 
this triphosphate form is utilized by retroviral DNA polymerase (reverse transcriptase). The 3’ 
substitution makes subsequent 5’–› 3’ phosphodiester linkages impossible, AZT can thus act as a chain 
terminator of DNA synthesis. DNA polymerase alpha is 100 times less susceptible to inhibition by 
AZT triphosphate than is HIV reverse transcriptase, and this difference may account for the selective 
antiviral activity of AZT against HIV.
However, AZT has notable side effects as bone marrow toxicity leading to anemia and 
neutropenia, and these could be explained by the fact that AZT is a reasonable substrate for thymidine 
kinase (TK). Although the corresponding monophosphate has affinity Km similar to that of thymidine 
monophosphate for thymidylate kinase, it has a very low rate of phosphorylation (Vm) being about 
0.3% that of TMP. This resulted in a large build up of AZT–monophosphate, which has been 
suggested to be responsible for the inhibition of TMP conversion to thymidine di- and triphosphate 
by competitive inhibition. It has been proposed that this reduction in TTP levels may contribute to the 
anemia side effect by starving DNA synthesis (Yarchoan et al., 1986). Also during the therapy, the virus 
can be isolated which indicates that AZT may not suppress production completely in vivo (Yarchoan et 
al., 1986). Finally, HIV-1 develops resistance to AZT in vitro after serial passages of the virus in the 
presence of the drug (Crumpacker, 2001). It is well known that reduction of the azido group of AZT 
gave a poor potency to the nucleoside. To improve the first phosphorylation step of this new 
nucleoside analogue, the L-alanine methyl ester phenyl phosphoramidate will be synthesized as a 
protide.
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Also Carbocyclic nucleosides exhibit antiviral activity against HIV or HSV. The carbocyclic 
nucleosides of the 2′, 3′-unsaturated series are potent inhibitors of HIV. In particular, the carbocyclic 
nucleoside analogue carbovir (CBV) has been shown to act as a potent and selective anti-HIV agent as 
it acts as a chain terminator agent.
Carbovir is a highly selective carbocyclic nucleoside analogue inhibitor of HIV replication in 
human lymphocytes and is potentially useful in the treatment of AIDS (Vince et al., 1998). CBV 
undergoes cellular metabolism to its mono-, di- and triphosphates. CBV triphosphate inhibits HIV-1 
reverse transcriptase at concentrations similar to those observed with 3′-azido-3′-deoxythymidine 
triphosphate, and lacks significant activity against human DNA polymerases and DNA primases. This 
virus-specific activity provides an explanation for the selective anti-HIV activity of CBV (Mahony et 
al., 1992). However it was removed from clinical trials due to apparent cardiotoxicity.
To probe SARs in operation reduction of the carbocyclic ring may be of interest. The 
corresponding L-alanine methyl ester prodrug will also be synthesized.
MATERIALS AND METHODS
General Methods 
The following anhydrous solvents and reagents were bought from Aldrich with secured seal stoppers: 
Dichloromethane (DCM), diethyl diethyl ether (Et2O), tetrahydrofuran (THF), N-methylimidazole 
(NMI), methanol (MeOH), dimethylformamide (DMF), pyridine (pyr), tBuMgCl, acetonitrile 
(CH3CN), and triethylamine (NEt3).
Chromatography 
Thin layer chromatography (TLC) was performed on commercially available Merck Kieselgel 60F254  
TLC plates, and the separated components were visualized using ultra violet light (254 nm and 366 
nm). Column chromatography was performed using Woelm silica (32-63 mm) as the stationary phase.
Spectral Characterization 
Proton and Carbon-13 nuclear magnetic resonance spectra were recorded on a Brucker Avance 
DPX300 spectrometer with operating frequencies of 300 MHz and 75 MHz, respectively. 
Phosphorus-31 NMR spectra were recorded on a Brucker Avance DPX300 spectrometer operating at 
121 MHz, and are reported in units of δ relative to 85% phosphoric acid as the external standard, 
positive shifts are downfield. The following abbreviations are used in the assignment of NMR signals: 
s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad signal), dd (doublet of doublet), 
and dt (doublet of triplet). Low resolution mass spectra were run on a VG Platform II Fisons 
instrument (Fisons, Altrincham, UK) (atmosperic pressure ionization, electrospray mass 
spectrometry) in either negative or positive ion mode. High resolution mass spectrometry was 
performed as a service by Birmingham University, using fast atom bombardment (FAB).
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Standard Procedure A: Synthesis of Phosphorodichloridate species 
Dry triethylamine (1.0 mol. equiv.) and the appropriate substituted phenol (1.0 mol. equiv.), in dry 
diethyl ether (50 mL) were added dropwise to a stirred solution of dry diethyl ether (50 mL) containing 
phosphorus oxychloride (3.0 mol. equiv.) at -78 °C under nitrogen. Following the addition, the 
reaction mixture was allowed to slowly warm up to room temperature and stirred overnight. The 
solution was filtered under nitrogen and the solvent was removed under reduced pressure for at least 
20 minutes to leave the crude product as oil.
Standard Procedure B: Synthesis of Phosphorochloridate species 
Dry triethylamine (2.0 mol. equiv.) in dry DCM (20 mL) was added drop wise to a stirred solution of 
dry DCM (40 mL) containing (substituted or not) phenyl dichlorophosphate (1.0 mol. equiv.) and the 
appropriate amino acid salt (1.0 mol. equiv.), at -78 °C under nitrogen. Following the addition, the 
reaction mixture was allowed to slowly warm up to room temperature and stirred overnight. The 
solvent was removed under reduced pressure and the crude residue was resuspended in dry diethyl 
ether and filtered under nitrogen. The solvent was removed under reduced pressure to leave the crude 
product as oil.
Standard Procedure F: Synthesis of Acyclic-5’-phosphoramidate derivatives
The nucleoside (1.0 mol. equiv.) was dried by coevaporation with either dry pyridine or dry toluene (3 
x 5 mL), and then resuspended in dry pyridine/DMF (9:1). A 1.0 M solution of tBuMgCl in dry THF 
(1 mol. equiv.) was added and the reaction mixture was stirred under nitrogen at room temperature for 
15 minutes. A solution of the appropriate phosphochloridate in dry THF (3.0 mol. equiv.) was added 
and the reaction was stirred at room temperature for 12 hours. The solvent was then removed under 
reduced pressure and the crude residue was purified twice by column chromatography with 3% 
MeOH in DCM followed with 2% MeOH in DCM.
Standard Procedure G: Synthesis of Nucleoside-5’-phosphoramidate derivatives via the use of 
NMI
The nucleoside (1 mol. equiv.) was dried by azeotroping with anhydrous pyridine (3 x 5 mL), and then 
suspended in anhydrous THF (15 mL). To the solution was added N-methylimidazole (6 mol. equiv.), 
and the resulting solution stirred for 5 minutes. The phosphochloridate species (3 mol. equiv. solutions 
in THF) was added drop wise, and the resulting solution stirred at room temperature for 12 hours. The 
solvent was removed under reduced pressure. The crude product was purified by silica column 
chromatography. 
(5) Phenyl (methoxy-L-alaninyl) phosphorochloridate 
Prepared according to Standard Procedure B, from phenyl phosphorodichloridate (1.4 g, 8 mmol), dry 
triethylamine (1.7 mL, 16 mmol), L-alanine methyl ester hydrochloride (1.12 g, 8 mmol) and dry DCM 
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(2) [  -D-arabinofuranosyl-5-propane-Uracil]-5'-[phenyl methoxy-L-alaninyl]phosphate
Method 1 
Prepared according to Standard Procedure G, from netivudine-5'-[phenyl methoxy-alaninyl] 
phosphate (0.3 g, 0.65 mmol), NMI (0.45 mL, 0.65 mmol), phenyl (methoxy-L-alaninyl) 
phosphorochloridate (5) (1.32 mL of 0.194 g/mL solution, 1.95 mmol) and dry THF (10 mL). TLC 
(9% MeOH in CHCl3) showed the reaction was not complete in 12 hours. The crude residue was 
purified by column chromatography, using MeOH: CHCl3 (3:97) as eluent, to give the product a clear, 
colorless oil, which solidified to a white foam on trituration and coevaporation with diethyl diethyl 
ether (0.05 g, 0.06 mmol, 25%).
Method 2 
Netivudine-5'-[phenyl methoxy-alaninyl] phosphate (4) (110 mg, 0.09 mmol) was added to a solution 
of 3.5 mL of methanol in the presence of Pd (10% on C) in a hydrogen atmosphere. TLC (8% MeOH 
in CHCl3) showed the reaction to be complete after 12 hours. The palladium was filtered off and the 
crude product was purified by flash column chromatography using DCM/MeOH (99:1) to give yellow 
oil (33 mg, 0.09 mmol, 60%). 
δP (CD3OD) 4.3,4.6;  δH (CD3OD) 0.8 (CH2CH2CH3, 3H, m), 1.3 (CH2CH2CH3, 2H, m),1.5 
(CH3-CH, 3H, m), 2.2 (CH2CH2CH3, 2H, m), 3.4 (OCH3, 3H, s),3.6 (CHCH3, 1H, m), 3.9 (H5’, 2H, 
m), 4.1 (H4’, 1H, m), 4.2 (H3’, 1H, m), 4.4 (H2’, 1H, m), 6.2 (H1', 1H, m), 7.3 (Ar, 5H, m), 7.5 (H6, 
1H, s); δc  (CD3OD) 13.7 (CH3CH2), 18.4 (CH3CH), 19.6 (CH2CH3), 33.0 (CH2C), 42.6 (CHNH), 50.4 
(CH3O), 61.9 (C5’), 69.7 (C3’), 75.4 (C2’, C4’), 82.2 (C1’), 112.0 (C5), 115.7 (Ar), 123.6 (Ar), 130.1 (Ar), 
133.4 (C6), 152.5 (CO), 157.1 (Ar), 164.4 (CO), 170 (COMe); MS [(ES(+ve)]) found 550.3655 
(MNa(+)), C22H30N3O10PNa requires 550.3655; Analysis found C 50.21, H 5.87, N 7.98%, 
C22H30N3O10P requires C 50.10, H 5.73, N 7.97%.
(3) 1-  -D-arabinofuranosyl-5-propyl uracil
Netivudine (110 mg, 0.12 mmol) was added to a solution of 3.5 mL of methanol in the presence of Pd 
(10% on C) in a hydrogen atmosphere. TLC (8% MeOH in CHCl3) showed the reaction to be 
complete after 12 hours. The palladium was filtered off and the crude product was purified by flash 
column chromatography using DCM/MeOH (99:1) to give yellow oil (88 mg, 0.12 mmol, 100%). 
δ
H 
 (CDCl3) 0.8 (H9, 3H, m), 1.1 (H8, 2H, m), 2.2 (H7, 2H, m), 3.5 (H5’, 2H, m), 3.8 (H4’, 
1H, m), 3,8 (H3’, 1H, m), 4.1 (H2’, 1H, m), 6.1 (H1’, 1H, m), 7,6 (H6, 1H, s); δc (CDCl3) 13.7 (CH3), 
19.6 (CH2CH3), 33.0 (CH2CH), 61.9 (C5’), 69.7 (C3’), 75.4 (C2’, C4’), 82.2 (C1’), 115.0 (C5), 133.4 (C6), 
152.5 (CO), 164.4 (CO); MS [(ES(+ve)]) found 337.1855 (MNa+), C12H18N2O6Na requires 337.1855; 
Analysis found C 50.33, H 6.44, N 9.89%, C12H18N2O6 requires C 50.35, H 6.34, N 9.79%.
(4) Netivudine-5'-(phenyl methoxy-L-alaninyl) phosphate
Prepared according to Standard Procedure G, from netivudine (0.2 g, 0.33 mmol), NMI (0.45 mL, 0.99 
mmol), phenyl (methoxy-L-alaninyl) phosphorochloridate (5) (1.32 mL of 0.194 g/mL solution, 0.99 
mmol) and dry THF (10 mL). TLC (9% MeOH in CHCl3) showed the reaction was not complete in 
12 hours. An acid work-up was used, whereby the crude product was solubilized in DCM (20 mL), and 
washed with 0.2 M HCl solution (10 mL), water (10 mL). The organic layer was dried over MgSO4, 
filtered and reduced to dryness. The residue was purified by column chromotography, using MeOH: 
CHCl3 (3:97) as eluent, to give the product of clear, colorless oil, which solidified to white foam on 
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trituration and coevaporation with diethyl diethyl ether (0.089 g, 0.09 mmol, 35%). δP  (CD3OD) 4.3, 4.6, δH (CD3OD) 0.8 (CH2CH2CH3, 3H, m), 1.3 (CH2CH2CH3, 2H, m), 1.5 
(CH3-CH, 3H, m,), 2.2 (CH2CH2CH3, 2H, m), 3.4 (OCH3, 3H, s), 3.6 (CHCH3, 1H, m), 3.9 (H5’, 2H, 
m), 4.1 (H4’, 1H, m), 4.2 (H3’, 1H, m), 4.4 (H2’, 1H, m), 6.2 (H1', 1H, m), 7.3 (Ar, 5H, m),7.5 (H6, 1H, 
s); δc (CD3OD) 13.7 (CH3CH2), 18.4 (CH3CH), 19.6 (CH2CH3), 33.0 (CH2CH), 42.6 (CHNH), 50.4 
(CH3O), 61.9 (C5’), 69.7 (C3’), 75.4 (C2’, C4’), 82.2 (C1’), 115.0 (C5), 115.7 (Ar), 123.6 (Ar), 130.1 (Ar), 
133.4 (C6), 152.5 (CO), 157.1 (Ar), 164.4 (CO), 170 (COMe); MS [(ES(+ve)]) found 550.3655 
(MNa+), C22H30N3O10PNa requires 550.3655; Analysis found C 50.21, H 5.87, N 7.98%, 
C22H30N3O10P requires C 50.10, H 5.73, N 7.97%.
(6) Attempted synthesis of 1-  -D-arabinofuranosyl-5-(Z-propenyl) uracil 
Method 1 
Netivudine (100 mg, 15 mmol) was added to a solution of 3.5 mL of methanol in the presence of Pd 
(5% on C) Lindlar catalyst in a hydrogen atmosphere. The reaction mixture was stirred for 1 hour at 1 
atm. The palladium was filtered and the crude product was purified by flash column chromatography 
using DCM/MeOH (98:2) to give a mixture of (3) and (6) as yellow oil. 
δ
H 
 (CDCl3) 0.96 (H9, 3H, m), 1.1 (H8, 2H, m), 1.76 (H9, 3H, m), 2.2 (H7, 2H, m), 3.5 (H5’, 
4H, m), 3.8 (H4’, 2H, m), 3,8 (H3’, 2H, m), 4.1 (H2’, 2H, m), 5.65 (H8, 1H, m), 6.1 (H1’, 2H, m), 6.21 
(H7, 1H, m), 7.5 (H6, 1H, s), 7.6 (H6, 1H, s); δc (CD3OD) 13.7 (CH3), 19.6 (CH2CH3), 21.5 (CH3), 33.0 
(CH2CH), 61.9 (C5’), 69.7 (C3’), 75.4 (C2’, C4’), 82.2 (C1’), 115.0 (C5), 125.7 (CH=CH), 129.5 
(CH=CH), 133.4 (C6), 152.5 (CO), 164.4 (CO).
Method 2 
Netivudine (100 mg, 15 mmol) was added to a solution of 3.5 mL of THF in the presence of 
DIBAL-H. The reaction mixture was stirred for 12 hrs at 1 atm. The crude product was purified by 
flash column chromatography using DCM/MeOH (98:2) to give (3) as yellow oil. 
Method 3 
Netivudine (100 mg, 15 mmol) was added to a solution of 3.5 mL of methanol in the presence of 
Pd/CaCO3 in a hydrogen atmosphere. The reaction mixture was stirred for 30 min at 1 atm. The 
palladium was filtered and the crude product was purified by flash column chromatography using 
DCM/MeOH (98:2) to give a mixture of (3) and (6) as yellow oil. 
δ
H 
 (CDCl3) 0.96 (H9, 3H, m), 1.1 (H8, 2H, m), 1.76 (H9, 3H, m), 2.2 (H7, 2H, m), 3.5 (H5’, 
4H, m), 3.8 (H4’, 2H, m), 3,8 (H3’, 2H, m), 4.1 (H2’, 2H, m), 5.65 (H8, 1H, m), 6.1 (H1’, 2H, m), 6.21 
(H7, 1H, m), 7.5 (H6, 1H, s), 7.6 (H6, 1H, s); δc (CD3OD) 13.7 (CH3), 19.6 (CH2CH3), 21.5 (CH3), 33.0 
(CH2CH), 61.9 (C5’), 69.7 (C3’), 75.4 (C2’, C4’), 82.2 (C1’), 115.0 (C5), 125.7 (CH=CH), 129.5 
(CH=CH), 133.4 (C6), 152.5 (CO), 164.4 (CO).
Method 4 
Netivudine (100 mg, 15 mmol) was added to a solution of 3.5 mL of THF in the presence of BBN. 
The reaction mixture was stirred for 12 hrs at 1 atm. The crude product was purified by flash column 
chromatography using DCM/MeOH (98:2) to give netivudine as yellow oil. 
δ
H
 (CDCl3) 1.8 (H9, 3H, m), 3.66 (H5’, 2H, m), 3.91 (H4’, 1H, m), 3.65 (H3’, 1H, m), 4.28 
(H2’, 1H, m), 5.93 (H1’, 1H, m), 8.17 (H6, 1H, s).
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Method 5 
Netivudine (100 mg, 15 mmol) was dissolved in 3.5 mL of methanol and cooled to -78 0C. NiCl2 (15 
mmol, 1 eq.) was dissolved in hot methanol and added to the reaction mixture. NaBH4 (15 mmol, 1 
eq.) was added to the reaction mixture portion-wise over 3 min, and the reaction mixture held at -78 
0C for 30 min. The reaction mixture was then allowed to warm to RT. The crude product was purified 
by flash column chromatography using DCM/MeOH (98:2) to give (6) and netivudine yellow oil. 
δ
H
 (CDCl3) 1.76 (H9, 3H, m),1.8 (H9, 3H, m), 3.66 (H5’, 4H, m), 3.91 (H4’, 2H, m), 3.65 
(H3’, 2H, m), 4.28 (H2’, 2H, m), 5.93 (H1’, 2H, m), 5.65 (H8, 1H, m), 6.21 (H7, 1H, m), 8.17 (H6, 1H, 
s); δc (CD3OD), 1.2 (CH3), 10.5 (CH3), 61.9 (C5’), 69.7 (C3’), 75.4 (C2’, C4’), 82.2 (C1’), 88.9 (C≡C), 
115.0 (C5), 125.7 (CH=CH), 129.5 (CH=CH), 133.4 (C6), 152.5 (CO), 164.4 (CO).
(7) 3   -Amino-AZT-5'-[phenyl methoxy-L-alaninyl] phosphate
AZT-5'-[phenyl methoxy-L-alaninyl] phosphate (10) (138 mg, 0.27 mmol) was dissolved in MeOH (2 
mL) and 1, 3-propane dithiol (76 µL, 3.51 mmol, 13 eq.) was added. The mixture was kept under N2 
and triethylamine (113 µl, 10.53 mmol, 3 eq.) was then added. After 12 hours the solvent was removed 
under vacuo, and the product was purified by flash column chromatography by eluting with 10% 
MeOH in DCM to give the product as yellow oil (0.128 g, 98%). 
δP (CDCl3) 4.1, 4.5; δH (CDCl3) 1.25 (CH3CH, 3H, m,), 1.9 (CH3, 3H, d, J = 5Hz), 2.2 (H2, 
2H, m), 3.6 (CH3O, 3H, s), 3.8 (CHCH3, 1H, m), 4.1 (H5', 2H, m), 4.5 (H3', 1H, m), 4.6 (H4', 1H, m), 
6.2 (H1', 1H, m), 7.3 (H6', 1H, m), 7.35 (NHAA, 1H, bs), 10 (NH, 1H, bs); δc (CDCl3) 15.9 (CH3), 18.4 
(CH3CH), 36.6 (C2’), 43.9 (CH3 base), 42.7 (CHNH, 1H, bs), 43.9 (C3’), 62.7 (C5’), 78.2 (C1’), 82.8 
(C4’), 128 (Ar), 129.9 (Ar), 130 (Ar), 134.8 (C4), 152.6 (C2), 157 (Ar), 164.4 (C6), 170 (CH3O); MS 
[(ES(+ve)]) found 505.0678 (MNa+), C20H27N4O8PNa requires 505.0678; Analysis found C 49.80, H 
5.76, N 11.65%, C20H27N4O8P requires C 49.79, H 5.64, N 11.61%.
(8) AZT-5'-[phenyl methoxy-L-alaninyl] phosphate
Prepared according to Standard Procedure G, from AZT (0.2 g, 0.75 mmol), NMI (0.8 mL, 3.75 
mmol), phenyl (methoxy-L-alaninyl) phosphorochloridate (5) (2.32 mL of 0.194 g/mL solution, 3.75 
mmol) and dry THF (10 mL). TLC (9% MeOH in CHCl3) showed the reaction was not complete in 
12 hours. The crude residue was purified by column chromatography, using MeOH: CHCl3 (3:97) as 
eluent, to give the product as clear, colorless oil, which solidified to white foam on trituration and 
coevaporation with diethyl diethyl ether (0.238 g, 37 %). 
δP (CDCl3) 3.8, 3.9; δH (CDCl3) 1.25 (CH3CH, 3H, m), 1.9 (CH3, 3H, d, J = 5Hz), 2.2 (H2, 
2H, m), 3.6 (CH3O, 3H, s), 3.8 (CHCH3, 1H, m), 4.1 (H5’, 2H, m), 4.5 (H3’, 1H, m), 4.6 (H4’, 1H, m), 
6.2 (H1’, 1H, m), 7.3 (H6’, 1H, m), 7.35 (NHAA, 1H, bs), 10 (NH3, 1H, bs); δc CDCl3) 15.9 (CH3 base), 
18.4 (CH3NH), 32 (C2’), 42.7 (CHNH), 49 (C3’), 62.7 (C5’), 78 (C4’), 78.2 (C1’), 128 (Ar), 129.9 (Ar), 
130 (Ar), 134.8 (C4), 152.6 (C2), 157.8 (Ar), 164.4 (C6), 170.6 (CH3O); MS [(ES(+ve)]) found 329.9697 
(MNa+), C9H14N3O7PNa requires 329.9696; Analysis found C 35.29, H 4.69, N 13.78%, C9H14N3O7P 
requires C 35.19, H 4.59, N 13.68%.
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(9) Attempted Synthesis of 2', 3'-dihydrocarbovir-5'-[phenyl methoxy-L-alaninyl] phosphate
 
Prepared according to Standard Procedure F, from (11) (0.1 g, 0.33 mmol), tBuMgCl (1.0 M in THF: 
0.47 mL, 0.47 mmol), phenyl (methoxy-L-alaninyl) phosphorochloridate (5) (1.31 mL of 0.196 g/mL 
solution, 1.29 mmol) and dry Pyridine/DMF (9/1 mL). TLC (6% MeOH in CHCl3) showed the 
reaction to be completed after 12 hours. The crude residue was purified by column chromatography, 
using MeOH:CHCl3 (3:97) as eluent, to give the product as a clear, colorless oil, which solidified to a 
white foam on trituration and coevaporation with diethyl diethyl ether (0.123 g, 0.2 mmol, 53%). 
δP (DMSO) 4.76, 4.987 and 8.89; δH (DMSO) 1.47 (H6’, 2H, m), 1.59 (H4’, 1H, m), 1.91 (H3’, 
2H, m), 1.95 (H2’, 2H, m), 3.49 (H5’, 2H, m), 3.71 (H1’, 1H, m), 7.57 (H8, 1H, s).
(10) 2', 3'-dihydrocarbovir
Carbovir (81.5 mg, 0.15 mmol) was added in a solution of 3.5 mL of methanol in the presence of Pd 
(10% on C) in a hydrogen atmosphere. TLC (8% MeOH in CHCl3) showed the reaction to be 
completed after 12 hours. The palladium was filtered off and the crude product was purified by flash 
column chromatography using DCM/MeOH (98:2) to give yellow oil (77 mg, 0.15 mmol, 100%). 
δP (CD3OD) 1.9 (H3', 2H, m), 2.1 (H4', 1H, m), 2.2 (H6’, 2H, m), 2.3 (H2’, 2H, m), 3.6 (H5’, 
2H, m), 4.8 (H1’, 1H, m), 7.7 (H8, 1H, s); δc (CD3OD) 24.1 (C2’), 24.2 (C3’), 34.6 (C′6), 38.5 (C4’), 39.4 
(C2’), 64.6 (C5’), 136.2 (C8), 137 (C4), 140 (C5), 163 (C2), 170 (CO); MS [(ES(+ve)]) found 286.0452 
(MNa+), C12H17N5O2Na requires 286.0455; Analysis found C 54.84, H 6.61, N 26.7%, C12H17N5O2 
requires C 54.74, H 6.51, N 26.6%.
RESULTS AND DISCUSSION
Synthesis of  Pronucleotides  of  Non Guanosine Nucleoside Analogues as Potential Antiviral 
Agents
The method of coupling to the nucleoside devised by Van Boom was used (Van Boom et al., 1975), 
employing N-methylimidazole (NMI) as a catalyst. 
The mechanism of action of the NMI was described by Farrow et al. (1990). This clean synthetic 
route has been applied to some modified thymidine analogues, as discussed below.
Synthesis of the 1- -D-arabinofuranosyl-5-propyl uracil-5'-[phenyl methoxyalaninyl] 
phosphate (2)
 
There were two different methods by which this target could be accessed. The first method was to 
synthesize the hydrogenated nucleoside, then to phosphorylate the 5'-position which is described in 
Figure 1. 
The phosphoramidate was synthesized by using the N-methylimidazole (NMI) route. With the 
help of NMI, the 5'-hydroxyl is sufficiently nucleophilic to attack the highly reactive 
phosphorochloridate, but as there are other functional groups capable of reacting in this way such as 
2' or 3'-hydroxyl group, a mixture of side products including 3'-phosphoramidate were detected. The 
identification of the two products was done by phosphorus and proton NMR. The unusual down field 
displacement of the 5′-proton and the 3′-proton (≈ 6 ppm instead of 4 ppm), proved the presence of 
the phosphorus on the 3′ and the 5′ corresponding hydroxyls. This was nicely shown by phosphorus 
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NMR with a close displacement of about 2.9 ppm and 3.4 ppm, each signal was doubled thus showing 
the diastereoisomers. The purification of this side product was found to be difficult because it had the 
same Rf as the desired compound. As the 5' primary hydroxyl group reacts faster than the secondary 
3'-hydroxyl group, it was possible to stop the formation of the side product by controlling the time of 
the reaction. The reaction was stopped before its completion, to avoid any 3’-OH coupling formation. 
An aqueous work-up of the reaction mixture was carried out to remove the NMI, but the high 
solubility of the product in water may also account for the low yield of the phosphorylated product.
 
Fig. 1. Phosphorylation of the saturated compound (Method 1).
The second way to obtain the saturated phosphoramidate was to synthesize the nucleotide first, 
and then to hydrogenate the triple bond, as shown in Figure 2.
The hydrogenation of the phosphoramidate was left for 12 hours; longer hours may reduce the 
phosphorus bond. The non-hydrogenated (4) product and the desired reduced phosphoramidate (2) 
seemed to have the same Rf. In order to get a better purification by column chromatography, it is 
preferable to follow the first procedure due to the instability of the phophoramidate.
Attempted Synthesis of 1-  -D-arabinofuranosyl-Z-propenyluracil (6) 
It was also of interest to synthesize the 5-vinyl netivudine derivative phosphoramidate (6) and to test 
its activity. In order to obtain a compound (6), an attempt was made to partially reduce 
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the 5-alkyl chain of netivudine. However, this could not be achieved although several methods were 
used. Initially, the standard method of reduction was carried out using the Lindlar catalyst (5% 
palladium on calcium carbonate poisoned with lead) (Robins and Barr, 1983; Shuto et al., 1997) 
However, the NMR showed that the saturated compound was formed along with the desired vinyl 
compound. Unfortunately, those compounds had the same Rf on TLC and hence could not be 
separated. A second method was employed using the DIBAL-H reagent (Eisch and Kaska, 1966). This 
afforded the unreacted starting material. This might be due to the bulkiness of the reagent which could 
not approach the triple bond. A third method was the use of palladium on calcium carbonate in the 
presence of quinolinen (Taylor and Yoon, 1994). Here again, a mixture of the saturated compound and 
the desired product were isolated. The use of BBN (Pelter et al., 1991) faced the same problem as in 
the case of DIBAL and no reaction was observed. Tanaka et al. (1991) have done similar work on a 
5-modified pyrimidine analogue, and have found that the reduction of the propynyl to the propenyl 
could only be achieved when the chain was situated at C-6 (Tanaka et al., 1991). This could be 
explained by the position of this triple bond situated between two groups with different effects: On 
one side, at C-4, a ketone with an electron withdrawing effect weakens the triple bond and makes it 
easy to hygrogenate, and on the other side, at N-1, a donating mesomoric effect increases the strength 
of this triple bond that has to be reduced. A hydrogenating agent such as DIBAL will not be efficient 
enough and a strong agent such as the lindlar catalyst would saturate the triple bond. A last trial was 
undertaken using NiCl2 and NaBH4, in place of palladium, a reduction system which releases a known 
amount of hydrogen into the reaction mixture and transiently forms a catalyst in situ (Lee et al., 2000). 
As was described, the reaction was stopped before the saturated compound was formed. 
Unfortunately, the similar Rf of the starting material and the desired product made the isolation of the 
vinyl compound difficult.
Fig. 2. Reduction of the phosphoramidate (Method 2).
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Attempted Synthesis of 1-  -D-arabinofuranosyl-Z-propenyluracil (6) 
It was also of interest to synthesize the 5-vinyl netivudine derivative phosphoramidate (6) and to test 
its activity. In order to obtain a compound (6), an attempt was made to partially reduce the 5-alkyl 
chain of netivudine. However, this could not be achieved although several methods were used. 
Initially, the standard method of reduction was carried out using the Lindlar catalyst (5% palladium on 
calcium carbonate poisoned with lead) (Robins and Barr, 1983; Shuto et al., 1997) However, the NMR 
showed that the saturated compound was formed along with the desired vinyl compound. 
Unfortunately, those compounds had the same Rf on TLC and hence could not be separated. A 
second method was employed using the DIBAL-H reagent (Eisch and Kaska, 1966). This afforded the 
unreacted starting material. This might be due to the bulkiness of the reagent which could not 
approach the triple bond. A third method was the use of palladium on calcium carbonate in the 
presence of quinolinen (Taylor and Yoon, 1994). Here again, a mixture of the saturated compound and 
the desired product were isolated. The use of BBN (Pelter et al., 1991) faced the same problem as in 
the case of DIBAL and no reaction was observed. Tanaka et al. (1991) have done similar work on a 
5-modified pyrimidine analogue, and have found that the reduction of the propynyl to the propenyl 
could only be achieved when the chain was situated at C-6 (Tanaka et al., 1991). This could be 
explained by the position of this triple bond situated between two groups with different effects: On 
one side, at C-4, a ketone with an electron withdrawing effect weakens the triple bond and makes it 
easy to hygrogenate, and on the other side, at N-1, a donating mesomoric effect increases the strength 
of this triple bond that has to be reduced. A hydrogenating agent such as DIBAL will not be efficient 
enough and a strong agent such as the lindlar catalyst would saturate the triple bond. A last trial was 
undertaken using NiCl2 and NaBH4, in place of palladium, a reduction system which releases a known 
amount of hydrogen into the reaction mixture and transiently forms a catalyst in situ (Lee et al., 2000). 
As was described, the reaction was stopped before the saturated compound was formed. 
Unfortunately, the similar Rf of the starting material and the desired product made the isolation of the 
vinyl compound difficult.
Synthesis of 3’-amino thymidine derivative-5'-[phenyl methoxyalaninyl] phosphate (7)
 
Before reducing the 3'-azido group of the nucleotide, the first step of this synthesis was to produce the 
phosphoramidate, otherwise the 3'-amino group of the modified AZT could also be phosphorylated. 
The phosphorylation was followed by a reduction using excess propane-1, 3-dithiol in the presence of 
triethylamine, to give the required 3'-amino phosphoramidate (7) as shown in Figure 3.
 These steps were easily undertaken: the first step was carried out using the standard method. 
After purification of the desired product by column chromatography, the protide was isolated in a 
quantitative yield of 60%, the remaining 40% was the unreacted starting material, and no by-product 
was isolated. The second step led to reduction of the azido group with high yield. Due to the different 
Rf of the starting material and the desired product, an easy purification was then undertaken. The 
purity of (7) was checked by HPLC and the presence of the amino group was identified by Infra Red: 
two weak bands asymmetric at 3372 cm-1 and symmetric at 3290 cm-1, characteristic of a primary 
amine.
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Synthesis of Pronucleotides of Guanine Nucleoside Analogues as Potential Antiviral Agents
 
The synthesis of those compounds required a different approach to the strategies previously employed 
for thymidine derived compounds due to the presence of the 2-amino group. The primary amino 
group confers two negative synthetic effects:
   1) Solubility: the amino group reduces the solubility of all unprotected guanosine derivatives in 
organic solvents. This can be overcome by using a more polar solvent, if the reaction conditions 
tolerate such a change. Alternatively, the addition of a lipophilic protecting group to the nitrogen will 
significantly increase the solubility of the compound. This creates other problems, considering that the 
protecting group must be stable to the reaction conditions of the synthesis and that the final product 
must be stable to the cleavage conditions of the protecting group. In addition, the introduction of 
protection and deprotection steps may reduce the overall yield.
   2) Reactivity: the primary aromatic amine provides an additional nucleophilic functional group to the 
nucleoside system. Previous work was undertaken with the acyclic nucleoside analogue acyclovir in 
order to investigate the use of N-protection as a mean to increase the solubility of acyclovir and to 
prevent also the N-phosphorylation on the guanine base. However, these synthetic routes made by 
Perry (1996), were lengthier and synthesis with N-protection, phosphorylation and then deprotection 
resulted in poor yields of the desired 5'-phosphoramidate derivative. Phosphorylation of unprotected 
acyclovir using NMI in THF previously resulted in little/no product being formed or isolated. A 
variety  of protecting  groups, also  made by Perry  (1996); (DMF  pixyl, N,  N- DMF- dimethylacetal)
Fig. 3. Synthesis of 3′-amino thymidine derivative-5'-[phenyl methoxyalaninyl] phosphate (7).
54
55 / Alshaimaa Hassan Abdallah and Christopher McGuigan.
(Perry, 1996; McGuigan et al., 2000), have been utilized to N-protect the base and increase the 
solubility in the phosphorylation reaction. The removal of these protecting groups in the presence of 
the phosphoramidate proved to be challenging due to the base cleavage of the ester groups. Harsh 
basic and acidic conditions will remove the ester groups on the phosphoramidate. Thus, it is desirable 
to achieve a one-step method for the formation of the 5'-phosphoramidates of guanine nucleoside 
analogues without the need of protecting groups and regardless of the solubility of the nucleoside to 
be derivatized. 
The method of Uchiyama et al. (1993), which claims to achieve selective O-phosphorylation 
without the need for N-protection of nucleoside, was investigated. This approach is based upon the 
concept of functional group activation rather than protection. Thus, when a nucleoside is treated with 
one equivalent of a strong metallo-organic base, an equilibrium mixture of the metal alkoxide and 
amide is formed. Selective O-phosphorylation depends on this equilibrium and the enhanced 
nucleophilicity of the oxygen function. Due to a stability reason, preferential formation of the 
magnesium iminoxide is observed with guanosine, but the magnesium alkoxide is more reactive. In 
addition, the phosphoryl iminoxide (or phosphorimidate) is not thermodynamically stable, undergoing 
isomerization to the phosphate and the subsequent phosphorylated species equilibrate to form a single 
phosphorylated product (the desired O-phosphorylation). Thus, application of this method to 
unprotected guanine nucleoside analogues was undertaken. When 1 equivalent of the Grignard base 
was employed as the activator of the Guanine base; the major less reactive amide and the minor more 
reactive magnesium alkoxide were simultaneously phosphorylated under the reaction conditions to 
give a mixture of N- and O-phosphorylation. Conversion of the phosphoryl iminoxide then took place 
slowly to give a single phosphorylating product. 
Attempted Synthesis of 2', 3’-dihydrocarbovir-5'-[phenyl methoxyalaninyl] phosphate (9) 
The 2', 3'-double bond was reduced prior to phosphorylation. It was observed that the hydrogenation 
was very fast with palladium on carbon, when used as a catalyst at 3 atmospheric pressures with a yield 
of 53%. The hydrogenation was carried out in methanol, but the next step of the synthesis needed an 
aprotic solvent, knowing that Grignard reagents and phosphorochloridates are unstable in methanol. 
It was observed that this reaction was very slow in THF due to the poor solubility of dihydrocarbovir 
in THF, whereas in pyridine the compound reacted in 12 hours at RT (Figure 4). The reaction mixture 
could not be purified using chromatography (FC or TLC), as the components of the mixture had 
similar Rf values.
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Fig. 4. Attempted synthesis of 2', 3'-dihydrocarbovir-5' [phenyl methoxyalaninyl] phosphate.
Biological Results 
All compounds were assayed for their antiviral activities by Drs J. Balzarini and E. DeClercq at the Rega 
Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium (Balzarini et al., 1996). 
The EC50 is the effective concentration required to cause a 50% inhibition of the virus–induced 
cytopathic effect in the cell culture. The CC50 is the cytotoxic concentration required for 50% inhibition 
of cell growth.
Antiviral Evaluation of 3’-amino-3’ deoxy-thymidine-5'-[phenyl methoxyalaninyl] phosphate (7)
As shown in Table 1, the replacement of the 3’-azido by primary amine functionality leads to a huge 
decrease in activity of the phosphoramidate. Moreover, this reduction in potency cannot be overcome 
by use of the phenoxy-L-methyl alaninyl ester phosphoramidate, as a potential kinase by-pass strategy. 
Several explanations are possible: The reduced nucleoside may be a poor substrate for nucleoside 
kinases, leading to a little intracellular 3’-amino-monophosphate and the phosphoramidate may be a 
poor intracellular source of the 3’-amino-monophosphate.
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Table 1. Antiviral evaluation of 3′-amino-2′-deoxy-thymine-5'-[phenyl methoxyalaninyl] phosphate 
(7) and the 1-   - D-arabinofuranosyl-5-propyl uracil-5'-[phenyl methoxyalaninyl] phosphate (2).
 
Alternatively, subsequent intracellular phosphorylation of the monophosphate of the amino 
nucleoside could be slow, or the competitive nucleoside triphosphate (NTP) could not be an effective 
inhibitor of HIV reverse transcriptase. At this stage, it is not possible to clarify which, if any, of these 
explanations is more likely.
 The synthesis of the 1-  -D-arabinofuranosyl-5-propyl-uracil-5'-[phenyl methoxyalaninyl] 
phosphate (2) phosphoramidate as shown in Table 1 did not improve its activity against HIV-1 or 2. 
The fact that the prodrug did not prove any selectivity may mean that it is not metabolized by the 
cell, thus it is not recognized specifically by the enzymes needed to inhibit the virus.
CONCLUSION
The biological results described here, demonstrate the lack of successful kinase by-pass of 
phosphoramidate derivatives of nucleoside analogues such as dihydro CBV, 3′-amino thymidine, or a 
5-propyl netivudine derivative. The reasons for this are presently unclear, but may be related to 
differences in the activating enzymes in different cell lines. 
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CEM cells (µM)  
 EC50 HIV-1 EC50 HIV-2 CC 50 
(7) >50  >50  225 
AZT 0.005 0.008 >100  
AZT protide (10)  0.055 0.07 >50  
(2) 1.6 1.2 250 
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